Alphyn is advancing therapy for skin diseases with its patent pending plant-derived technology platform. Alphyn solves 2 of the largest medical challenges to human kind - infectious skin diseases, including drug resistant infections & skin cancer - with combined target markets of $13 billion (first addressable segments $3.7 billion). Pilot human results demonstrate success for MRSA drug resistant skin infection and basal cell skin cancer, without current therapy problems. There hasn’t been a new topical MRSA drug for 30 years – underscoring market demand for Alphyn’s MRSA product. Alphyn’s basal cell skin cancer product is the first to not damage skin. Alphyn’s products are botanical drugs; they follow FDA botanical guidelines that eliminate most of the standard drug pre-clinical testing. This enables Alphyn to start FDA regulatory drug approval at Phase II clinical trial. Alphyn’s path to FDA approval is 50% faster, 50% less cost versus standard drugs with QIDP 10 years exclusivity.